| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Henry Schein Inc$86.51
+0.76 (+0.89%)
Market Cap
8.64 B
EPS
3.29
P/E Ratio
23.04 $
Value Trade
87.60 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.37 B
Operating CF
-97.00 M
Total Assets
11.30 B
Total Liabilities
6.48 B
Equity
3.27 B
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
138.00 M
Monthly Burn
32.33 M
Runway
1.5 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.90 M
52 Week Range
61.95 - 89.29
% held by Insiders
15.22 %
% held by Institutions
94.04 %
Enterprise Value
13.47 B
Total Shares
113.88 M
Short %
6.72 %
Float Shares
97.25 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HSIC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HSIC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-HSIC
Aug 4, 2026▲ +0.9%today
Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
Henry Schein, Inc. reported robust financial results for the second quarter of 2026, highlighting strong sales performance and margin improvements. The company experienced accelerated internal local currency sales growth compared to the previous quarter. Additionally, Henry Schein raised its guidance for the full fiscal year 2026, indicating positive momentum across its business segments.
Read more →-HSIC
Jul 30, 2026Henry Schein Announces Leadership Transitions
Henry Schein, Inc. has announced the establishment of the Henry Schein Leadership Team (HSLT) to replace its Executive Management Committee. This new leadership structure aims to integrate the global supply chain with the distribution group, enhancing collaboration and execution of the company's strategic priorities.
Read more →-HSIC
Jul 21, 2026Henry Schein to Webcast Second Quarter 2026 Conference Call on Tuesday, August 4, 2026, at 8:00 a.m. ET
Henry Schein, Inc. will announce its second quarter 2026 financial results on August 4, 2026, prior to market opening. The company will host a live webcast of its earnings conference call at 8:00 a.m. ET, featuring CEO Fred Lowery among the speakers. This event emphasizes the company's commitment to transparency with investors.
Read more →-HSIC
Jun 30, 2026GoTu and Henry Schein Announce Strategic Partnership to Strengthen Dental Workforce Support Nationwide
GoTu Technology and Henry Schein, Inc. have announced a strategic partnership to enhance staffing solutions for dental practices facing workforce shortages. This collaboration allows dental offices to access GoTu's platform for temporary and permanent staffing needs, aiming to improve operational efficiency and patient care. The partnership reflects a commitment to support the dental ecosystem amid ongoing staffing challenges.
Read more →-HSIC
May 22, 2026Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board
Henry Schein has announced the election of William K. 'Dan' Daniel as the Independent Chairman of the Board. This leadership change is expected to guide the company in its future endeavors. The announcement reflects the company's commitment to strong governance and leadership.
Read more →-HSIC
May 22, 2026HENRY SCHEIN ANNOUNCES THE ELECTION OF WILLIAM K. "DAN"
Henry Schein, Inc. announced the election of William K. 'Dan' Daniel as Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who has served 44 years as a Director and is now Chairman Emeritus. Daniel, who joined the board in May 2025, is noted for his extensive leadership experience in healthcare, especially from his time at Danaher Corporation. The appointment positions Henry Schein for continued growth as it advances its comprehensive healthcare solutions.
Read more →-HSIC
May 5, 2026Henry Schein Reports First Quarter 2026 Financial Results
Henry Schein has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance, but lacks specific details on revenue, profit, or strategic initiatives. Further analysis may be required to understand the implications of these results.
Read more →-HSIC
May 5, 20261- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ● Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 ● Q1 2026 non-GAAP diluted EPS of $1
Henry Schein, Inc. reported its financial results for the first quarter of 2026, showing a GAAP diluted EPS increase to $0.92 compared to $0.88 in Q1 2025. The company reaffirmed its 2026 financial guidance, predicting continued growth driven by value-creation initiatives expected to yield over $200 million in operating improvements. The report indicates a sales growth of 6.3% year over year, demonstrating strong momentum in key areas of the business. Henry Schein's focus on technology and operational execution aims to enhance its market position and profitability going forward.
Read more →-HSIC
Apr 21, 2026Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET
Henry Schein, Inc. will release its first quarter 2026 financial results on May 5, 2026, before the market opens. A live webcast of the earnings conference call will begin at 8:00 a.m. ET, featuring CEO Frederick M. Lowery and CFO Ronald N. South. Investors can access the call via the company's investor website.
Read more →-HSIC
Feb 24, 20261- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND INTRODUCES 2026 FINANCIAL GUIDANCE ● Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS
Henry Schein, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant growth across its business segments. The company achieved a GAAP diluted EPS of $0.85, an increase from $0.74 in the same quarter last year, along with a non-GAAP EPS of $1.34. Total sales for Q4 2025 rose by 7.7% year-over-year, driven by robust performances in global equipment and specialty products. Additionally, Henry Schein introduced its financial guidance for 2026, projecting further sustained growth.
Read more →-HSIC
Jan 22, 2026Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET
Henry Schein, Inc. will release its fourth quarter 2025 financial results on February 24, 2026, before the market opens. A live webcast of the earnings conference call will begin at 8:00 a.m. ET, featuring CEO Stanley M. Bergman and CFO Ronald N. South. Investors can access the call online, with a replay available afterward.
Read more →-HSIC
Jan 12, 2026Henry Schein Names Frederick M. Lowery as Chief Executive Officer Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence MELVILLE, N.Y.
Henry Schein, Inc. announced the appointment of Frederick M. Lowery as its new Chief Executive Officer, effective March 2, 2026. Lowery, a healthcare distribution veteran with over 20 years of experience, will succeed Stanley M. Bergman, who has served as CEO for 35 years. The transition aims to build on Henry Schein's reputation for innovation and customer service while executing its strategic plan for growth. Lowery's past leadership roles include significant positions at Thermo Fisher Scientific and other major corporations, aligning with the company's objectives moving forward.
Read more →-HSIC
Dec 23, 2025Henry Schein Provides Update on CEO Search Process MELVILLE, N.Y.
Henry Schein, Inc. is nearing the conclusion of its search for a new CEO, with plans to finalize the appointment by mid-January 2026. The Lead Director, Philip A. Laskawy, expressed satisfaction with the progress and the quality of candidates considered. Until a successor is appointed, current CEO Stanley Bergman will continue in his role, focusing on maintaining business momentum during the transition. The company operates globally, providing healthcare solutions largely to dental and medical practitioners.
Read more →-HSIC
Nov 4, 2025▲ +10.8%on this news
1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD THIRD QUARTER 2025 FINANCIAL RESULTS AND RAISES FULL YEAR NON-GAAP EPS GUIDANCE ● Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in
Henry Schein, Inc. (HSIC) reported record financial results for the third quarter of 2025, with GAAP diluted EPS rising to $0.84 from $0.78 in Q3 2024. The company raised its guidance for non-GAAP diluted EPS for the full year to a range of $4.88 to $4.96 and announced initiatives aimed at delivering over $200 million in operating income improvements. Sales growth was reported across all segments, with particularly strong increases in Global Technology and Dental Distribution. Additionally, an agreement was reached allowing KKR to increase its stock ownership to 19.9%.
Read more →-HSIC
Aug 5, 2025▼ -7.4%on this news
AUGUST 5, 2025 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the s
Henry Schein, Inc. reported its financial results for the second quarter of 2025, with GAAP diluted EPS at $0.70, down from $0.80 in the same quarter last year. The company maintained its guidance for 2025 non-GAAP diluted EPS between $4.80 and $4.94, highlighting a 3.3% increase in total net sales. Despite strong performance in Global Medical Distribution, lower margins and impacts from pricing strategies were noted. Henry Schein remains focused on operational efficiency through its collaboration with KKR and has plans for future strategic enhancements.
Read more →-HSIC
Jul 15, 2025Stanley M. Bergman to Retire as Henry Schein s Chief Executive Officer at the End of 2025 Mr. Bergman to Continue to Serve as Chairman of the Board MELVILLE, N.Y.
Stanley M. Bergman, the CEO of Henry Schein, Inc., will retire at the end of 2025 after a 45-year tenure, including over 35 years as CEO. He will remain the Chairman of the Board and has expressed gratitude for his time with the company. Under his leadership, Henry Schein grew its revenue from $225 million in 1989 to nearly $13 billion in 2024. The Board is beginning a formal search for his successor, emphasizing the company's strategic plans for future growth and development.
Read more →-HSIC
May 5, 2025HENRY SCHEIN 1Q 2025 QUARTERLY 8-K exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first qua
Henry Schein reported its financial results for Q1 2025, featuring a 22% growth in GAAP diluted EPS to $0.88 and a 4.5% increase in non-GAAP diluted EPS to $1.15. The company maintained its financial guidance for the year, projecting a non-GAAP diluted EPS between $4.80 and $4.94. Despite a general decline in sales reported as affected by currency fluctuations and equipment sales decreases, certain divisions saw growth, particularly in medical distribution and technology solutions. However, the company also faced restructuring costs and challenges in their dental distribution segment.
Read more →-HSIC
May 2, 2025Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors MELVILLE, N.Y., May 16 th , 2025 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of hea
Henry Schein, Inc. has successfully completed a $250 million strategic investment from KKR, which now holds about 12% of the company shares. In conjunction with this investment, Dan Daniel has been appointed to the Board of Directors, alongside Max Lin. Both appointees bring extensive experience in health care and operations, and their involvement is expected to drive the company's strategic growth. This development is seen as a significant step in Henry Schein's BOLD+1 strategy aimed at creating long-term value.
Read more →-HSIC
Feb 25, 2025FEBRUARY 25, 2025 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES DETAILED 2025 FINANCIAL GUIDANCE Fourth-quarter 2024 GAAP di
Henry Schein, Inc. (Nasdaq: HSIC) reported its fourth quarter and full-year financial results for 2024, highlighting a GAAP diluted EPS of $0.74 and robust operating cash flow of $204 million for Q4, totaling $848 million for the year. The company outlined its 2025 financial guidance, projecting non-GAAP diluted EPS in the range of $4.80 to $4.94, alongside a strategic plan aimed at enhancing their portfolio and operational structure. Henry Schein also revised its reportable segments to provide clearer insights to investors, reflecting its commitment to delivering value and pursuing growth in health care solutions.
Read more →-HSIC
Jan 29, 2025HENRY SCHEIN ANNOUNCES STRATEGIC INVESTMENT BY KKR, BOARD CHANGES AND PROVIDES PRELIMINARY UNAUDITED FINANCIAL RESULTS AND 2025 FINANCIAL GUIDANCE KKR to become 12% common shareholder in Henry Schei
Henry Schein, Inc. has announced a strategic $250 million investment from KKR, making KKR a significant 12% shareholder. The investment is accompanied by changes to the Board of Directors, with new members having extensive experience in healthcare and finance. The company also provided preliminary financial results for 2024 and guidance for 2025, projecting revenue growth amidst ongoing operational enhancements. Additionally, Henry Schein updated its stock repurchase program, authorizing a $500 million increase.
Read more →-HSIC
Nov 5, 2024DATED NOVEMBER 5, 2024 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND INCREASES 2024 FINANCIAL GUIDANCE Third-quarter 2024 GAAP diluted EPS of $0.78
Henry Schein reported its financial results for Q3 2024, revealing a GAAP diluted EPS of $0.78, a decrease from the previous year. The company has increased its full-year non-GAAP EPS guidance to a range of $4.74 to $4.82. Key factors contributing to performance include successful strategic implementations and growth in high-margin products. However, some challenges remain, including a decline in sales from personal protective equipment and restructuring costs.
Read more →-HSIC
Aug 6, 2024▼ -8.1%on this news
DATED AUGUST 6, 2024 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND UPDATES 2024 FINANCIAL GUIDANCE Highlights: Second-quarter 2024 GAAP diluted EPS
Henry Schein, Inc. announced its second-quarter financial results for 2024, reporting a GAAP diluted EPS of $0.80 and updating its full-year non-GAAP EPS guidance to a range of $4.70 to $4.82. The company experienced a solid operating cash flow of $296 million, yet acknowledged challenges in sales recovery following a cyber incident last year. Despite a slight decrease in sales from PPE, Henry Schein remains optimistic about its long-term goals and has introduced a restructuring plan aimed at achieving substantial cost savings.
Read more →-HSIC
May 7, 2024MAY 7, 2024 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SOLID FIRST-QUARTER 2024 FINANCIAL RESULTS AND UPDATES 2024 FINANCIAL GUIDANCE First-quarter 2024 sales growth of 3.7%, GAAP dilute
Henry Schein reported a 3.7% growth in sales for the first quarter of 2024, driven by recovery from a recent cyber incident and new product innovations. The company has tightened its total sales growth guidance for 2024 to between 8% and 10%. Non-GAAP diluted EPS guidance remains steady at $5.00 to $5.16, reflecting an increase compared to 2023. Despite some decrease in sales due to lower PPE pricing and ongoing cyber incident impacts, the overall financial results indicate a solid performance.
Read more →-HSIC
Feb 27, 2024FEBRUARY 27, 2024 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FOURTH-QUARTER AND FULL-YEAR 2023 FINANCIAL RESULTS AND INTRODUCES 2024 FINANCIAL GUIDANCE Fourth quarter GAAP diluted EPS of
Henry Schein, Inc. reported its fourth-quarter and full-year financial results for 2023, noting a fourth-quarter GAAP diluted EPS of $0.13, down from previous results. The company anticipates growth in 2024, projecting a non-GAAP diluted EPS of $5.00 to $5.16, which represents an increase of 11% to 15% compared to 2023. Despite a decrease in total net sales due to a cybersecurity incident, the fourth-quarter performance reflects a solid recovery and growth in Technology and Value-Added Services.
Read more →-HSIC
Nov 16, 2023HENRY SCHEIN ANNOUNCES RECEIPT OF DEFICIENCY NOTICE FROM NASDAQ REGARDING REQUIREMENT TO TIMELY FILE QUARTERLY REPORT ON FORM 10-Q MELVILLE, N.Y.
Henry Schein, Inc. has received a deficiency notice from Nasdaq for failing to file its quarterly report on Form 10-Q in a timely manner due to a cybersecurity incident that occurred in October 2023. Despite this setback, the company anticipates that it will submit the overdue report before the end of November 2023. Nasdaq has provided a 60-day period for Henry Schein to develop a compliance plan. The company has been proactive in updating stakeholders regarding its situation.
Read more →-HSIC
Nov 13, 2023▲ +5.4%on this newsshared move
NOVEMBER 13, 2023 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL-YEAR GUIDANCE GAAP diluted EPS of $1.05 and non-GAAP diluted EPS of $1.
Henry Schein, Inc. reported its third-quarter 2023 financial results, highlighting stable net sales growth amidst challenging macroeconomic conditions. The GAAP diluted EPS stood at $1.05, while non-GAAP diluted EPS reached $1.32, showing a modest rise from the previous year. Despite the decline in sales of PPE products and COVID-19 test kits, the company noted progress in achieving its strategic objectives. However, they adjusted their earnings guidance due to market softness and ongoing consequences from a recent cybersecurity incident.
Read more →-HSIC
Nov 2, 2023HENRY SCHEIN TO WEBCAST THIRD QUARTER 2023 CONFERENCE CALL AND PROVIDE AN UPDATE ON ITS FULL-YEAR 2023 GUIDANCE ON MONDAY, NOVEMBER 13, 2023 AT 10:00
Henry Schein, Inc. has announced a webcast for its third quarter 2023 financial results on November 13, 2023, at 10:00 A.M. ET. The company will discuss its earnings guidance for the full year and address issues stemming from a recent cybersecurity incident that has caused delays in filing necessary financial documents. Key executives will speak during the call, emphasizing the company's strategy in communicating with investors despite operational challenges.
Read more →-HSIC
Oct 16, 2023Henry Schein Provides Information on Cybersecurity Incident MELVILLE, NEW YORK On Saturday, October 14, Henry Schein, Inc. (Nasdaq: HSIC) determined that a portion of its manufacturing and distribution businesses experie
Henry Schein, Inc. reported a cybersecurity incident affecting part of its manufacturing and distribution operations on October 14. The company acted quickly to contain the incident by taking certain systems offline, resulting in temporary business disruptions. Crucially, the practice management software utilized by their clients remained operational. Henry Schein is collaborating with external cybersecurity experts to investigate the situation and has notified law enforcement authorities.
Read more →-HSIC
Aug 7, 2023AUGUST 7, 2023 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SOLID SECOND-QUARTER 2023 FINANCIAL RESULTS AND AFFIRMS FULL-YEAR GUIDANCE Achieved internal sales growth of 3.3% in local curre
Henry Schein, Inc. (HSIC) reported a solid second-quarter financial performance for 2023, achieving internal sales growth of 3.3% in local currencies. The company affirmed its full-year non-GAAP diluted EPS guidance, amid lower revenue contributions from PPE products. The results were bolstered by strong demand in North American dental markets, including steady growth in technology and equipment sales. Despite overall positive results, the global medical segment saw a decline of 4.6% in sales compared to the previous year.
Read more →-HSIC
Jul 13, 2023HENRY SCHEIN ENHANCES LIQUIDITY POSITION WITH NEW $750 MILLION CREDIT FACILITY Amends Existing $1 Billion Credit Facility, Bringing Total Liquidity to $1.8 Billion MELVILLE, N.Y.
Henry Schein, Inc. has secured a new $750 million credit facility, amending its existing $1 billion revolving credit facility to enhance its liquidity position. This transaction brings the company's total liquidity to $1.8 billion, helping to support its strategic initiatives, including mergers and acquisitions. The amendments were accompanied by an extension of the maturity date for the existing facility to July 2028, reflecting confidence from lending partners in the company’s financial standing. The additional liquidity aims to facilitate further investment in growth opportunities.
Read more →-HSIC
May 9, 2023▼ -6.2%on this news
MAY 9, 2023 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS First-quarter 2023 net sales of $3.1 billion decreased 3.8% compared with first-quarter 2022;
Henry Schein reported its first-quarter financial results for 2023, indicating net sales of $3.1 billion, a decrease of 3.8% compared to the same period in 2022. Despite the dip in overall sales, the company experienced a strong internal growth of 6.3% in local currencies when excluding personal protective equipment (PPE) products. The chairman noted solid performance in the Dental and Technology sectors, although the company faced challenges from decreased PPE sales and acquisition-related expenses, impacting earnings per share. The updated guidance for non-GAAP diluted EPS for the full year reflects some dilution from a recent acquisition.
Read more →-HSIC
Feb 27, 2023HENRY SCHEIN, INC. TO DETAIL STRATEGIC PLAN AND LONG-TERM
Henry Schein, Inc. is hosting an Investor Meeting to unveil its BOLD+1 Strategic Plan aimed at sustainable growth and long-term financial goals. Executive leadership will provide insights into the company's achievements and future directives, emphasizing a digital transformation and a focus on higher-margin segments. The firm, a major health care solutions provider, aims to leverage strong market fundamentals and financial performance to capitalize on growth opportunities. Additionally, they caution that forward-looking statements come with inherent risks and uncertainties, especially regarding public health factors.
Read more →-HSIC
Feb 16, 2023▼ -6.6%on this news
FEBRUARY 16, 2023 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS AND INTRODUCES 2023 FINANCIAL GUIDANCE Fourth-quarter net sales of $3.4 b
Henry Schein, Inc. reported its fourth-quarter and full-year 2022 financial results, highlighting a net sales increase to $3.4 billion, representing a growth of 1.2% compared to the previous year. However, the company's GAAP diluted EPS decreased significantly from $1.05 to $0.34. Looking ahead, the company has introduced guidance for 2023, anticipating a non-GAAP diluted EPS of $5.25 to $5.42, despite challenges including declining sales of PPE products. Overall, the company maintains a stable outlook, particularly in its core dental and medical businesses.
Read more →-HSIC
Nov 1, 2022NOVEMBER 1, 2022 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD NON-GAAP THIRD-QUARTER 2022 DILUTED EPS FINANCIAL RESULTS Net sales of $3.1 billion decreased 3.5% compared with the th
HENRY SCHEIN REPORTS RECORD NON-GAAP THIRD-QUARTER 2022 DILUTED EPS Net sales of $3.1 billion decreased 3.5% compared with the third-quarter 2021; internal sales increased 6.8% in local currencies when excluding sales of PPE and COVID-19 test kits GAAP diluted EPS of $1.09 co
Read more →-HSIC
Aug 2, 2022AUGUST 2, 2022 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD SECOND-QUARTER 2022 FINANCIAL RESULTS Second-quarter net sales of $3.0 billion up 2.1% compared with second-quarter 2021;
HENRY SCHEIN REPORTS RECORD SECOND-QUARTER 2022 FINANCIAL RESULTS Second-quarter net sales of $3.0 billion up 2.1% compared with second-quarter internal sales up 6.7% in local currencies when excluding sales of PPE and other COVID-19 related products GAAP diluted EPS of $1.16
Read more →-HSIC
May 3, 2022MAY 3, 2022 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FIRST-QUARTER 2022 FINANCIAL RESULTS Total first-quarter 2022 net sales of $3.2 billion up 8.7% compared with first-quarter
HENRY SCHEIN REPORTS RECORD FIRST-QUARTER 2022 FINANCIAL RESULTS Total first-quarter 2022 net sales of $3.2 billion up 8.7% compared with first-quarter 2021 GAAP diluted EPS of $1.30 compared with first-quarter 2021 GAAP diluted EPS of $1.16 and first-quarter 2021 non-GAAP d
Read more →-HSIC
Apr 4, 2022HENRY SCHEIN ANNOUNCES RETIREMENT OF CHIEF ADMINISTRATIVE OFFICER AND APPOINTS CHIEF OPERATING OFFICER Gerald A. Benjamin will retire as Chief Administrative Officer Michael S. Ettinger
HENRY SCHEIN ANNOUNCES RETIREMENT OF CHIEF ADMINISTRATIVE OFFICER AND APPOINTS CHIEF OPERATING OFFICER MELVILLE, N.Y., April 4, 2022 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care solutions to office-based dental and medical practitioners, announ
Read more →-HSIC
Feb 15, 2022▲ +8%on this news
HENRY SCHEIN INC 4Q 2021 QUARTERLY 8-K FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD NON-GAAP FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS Fourth-quarter total net sales of $3.3 billion up 5.2% compared with p
HENRY SCHEIN REPORTS RECORD NON-GAAP FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS total net sales of $3.3 billion up 5.2% compared with prior-year GAAP diluted EPS from continuing operations of $1.05 compared with prior-year GAAP diluted EPS from continuing operations o
Read more →-HSIC
Jan 5, 2022HENRY SCHEIN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER AND RELATED SUCCESSION PLAN CFO Steven Paladino will retire on
HENRY SCHEIN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER AND RELATED SUCCESSION PLAN MELVILLE, N.Y., January 5, 2022 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care solutions to office-based dental and medical practitioners, announced today th
Read more →-HSIC
Dec 8, 2021HENRY SCHEIN APPOINTS SCOTT SEROTA TO BOARD OF DIRECTORS Former President and CEO of Blue Cross Blue Shield Brings Health Care Expertise MELVILLE, N.Y.
HENRY SCHEIN APPOINTS SCOTT SEROTA TO BOARD OF DIRECTORS Former President and CEO of Blue Cross Blue Shield Brings Health Care Expertise MELVILLE, N.Y., December 8, 2021 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care solutions to office-based de
Read more →-HSIC
Nov 2, 2021HENRY SCHEIN INC 3Q 2021 QUARTERLY 8-K FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD THIRD-QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Total net sales of $3.2 billion up 11.9% versus prior year GAAP dil
HENRY SCHEIN REPORTS RECORD THIRD-QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS net sales of $3.2 billion up 11.9% versus prior year diluted EPS from continuing operations of $1.15 versus prior-year GAAP diluted EPS from continuing operations of $0.99 diluted EPS
Read more →-HSIC
Aug 23, 2021HENRY SCHEIN ANNOUNCES NEW $1
HENRY SCHEIN ANNOUNCES NEW $1 BILLION CREDIT FACILITY MELVILLE, N.Y., August 23, 2021 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care products and services to office-based dental and medical practitioners, today announced that it has amended its r
Read more →-HSIC
Aug 3, 2021HENRY SCHEIN INC 2Q 2021 QUARTERLY 8-K FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD SECOND-QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Total net sales of $3.0 billion up 76.2% versus prior year and up
HENRY SCHEIN REPORTS RECORD SECOND-QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS net sales of $3.0 billion up 76.2% versus prior year and up 21.2% versus 2019 diluted EPS from continuing operations of $1.10 versus prior-year GAAP loss per diluted share from contin
Read more →-HSIC
May 4, 2021MAY 4, 2021 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FIRST-QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Total net sales of $2.9 billion up 20.4% versus prior year G
HENRY SCHEIN REPORTS RECORD FIRST-QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS net sales of $2.9 billion up 20.4% versus prior year GAAP diluted EPS from continuing operations of $1.16 versus prior-year GAAP diluted EPS from continuing Non-GAAP diluted EPS from
Read more →-HSIC
Feb 17, 2021FEBRUARY 17, 2021 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Total net sales growth of 18.6% in fourth quarter 2020 versu
HENRY SCHEIN REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS FROM CONTINUING OPERATIONS net sales growth of 18.6% in fourth quarter 2020 versus prior-year Record total net sales growth for second half of 2020 GAAP diluted EPS from continuing operations of $0.99 versus prior-yea
Read more →-HSIC
Feb 10, 2021HENRY SCHEIN ANNOUNCES TWO NEW DIRECTORS Mohamad Ali and Deborah Derby Appointed as Board Members MELVILLE, N.Y.
HENRY SCHEIN ANNOUNCES TWO NEW DIRECTORS Mohamad Ali and Deborah Derby Appointed as Board Members MELVILLE, N.Y., February 10, 2021 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care solutions to office-based dental and medical practitioners, announ
Read more →-HSIC
Nov 2, 2020NOVEMBER 2, 2020 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD THIRD QUARTER 2020 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Internal sales growth in local currencies of 13.0% driv
HENRY SCHEIN REPORTS RECORD THIRD QUARTER 2020 FINANCIAL RESULTS FROM CONTINUING Internal sales growth in local currencies of 13.0% driven by personal protective equipment and COVID-19- GAAP diluted EPS from continuing operations of $0.99 versus prior-year GAAP diluted EPS fro
Read more →-HSIC
Aug 4, 2020AUGUST 4, 2020 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Q2 GAAP loss per diluted share from continuing operations of $0.08 versus prior-year GAAP diluted EPS from con
HENRY SCHEIN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS per diluted share from continuing operations of $0.08 versus prior-year GAAP diluted EPS from continuing operations of $0.78 diluted EPS from continuing operations of $0.00 versus prior-year non-GAAP diluted EPS from
Read more →-HSIC
Jun 25, 2020HENRY SCHEIN AMENDS AND EXTENDS FINANCING FACILITIES Company Amends and Extends $350 Million Credit Facility and $1 Billion Private Placement Shelf Facilities MELVILLE, N.Y.
HENRY SCHEIN AMENDS AND EXTENDS FINANCING FACILITIES Company Amends and Extends $350 Million Credit Facility and $1 Billion Private Placement Shelf Facilities MELVILLE, N.Y., June. 25, 2020 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care solutions
Read more →-HSIC
May 5, 2020MAY 5, 2020 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Q1 GAAP diluted EPS from continuing operations of $0.91 versus prior-year GAAP diluted EPS from continuing operati
HENRY SCHEIN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Q1 GAAP diluted EPS from continuing operations of $0.91 versus prior-year GAAP diluted EPS from continuing operations of $0.78 Q1 non-GAAP diluted EPS from continuing operations of $0.94 versus prior-year non-GAAP dilut
Read more →-HSIC
Apr 20, 2020HENRY SCHEIN ENHANCES LIQUIDITY POSITION WITH NEW CREDIT FACILITY TOTALING $700 MILLION Company Also Amends Existing $750 Million Credit Facility; Total Liquidity Now at $1.7 Billion MELVILLE, N.Y.
HENRY SCHEIN ENHANCES LIQUIDITY POSITION WITH NEW CREDIT FACILITY TOTALING $700 MILLION Company Also Amends Existing $750 Million Credit Facility; Total Liquidity Now at $1.7 Billion MELVILLE, N.Y., April 20, 2020 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider
Read more →-HSIC
Feb 20, 2020FEBRUARY 20, 2020 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FOURTH QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS GAAP diluted EPS from continuing operations of $2.25, up 192.2 % over pri
HENRY SCHEIN REPORTS RECORD FOURTH QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS EPS from continuing operations of $2.25, up 192.2% over prior-year quarter, reflecting, among other things, a net gain on sale of equity investments diluted EPS from continuing opera
Read more →-HSIC
Nov 5, 2019NOVEMBER 5, 2019 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD THIRD QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS GAAP diluted EPS from continuing operations of $0.91, up 54.2 % over prior-
HENRY SCHEIN REPORTS RECORD THIRD QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS GAAP diluted EPS from continuing operations of $0.91, up 54.2% over prior-year Non-GAAP diluted EPS from continuing operations of $0.90, up 15.4% over prior-year range for 2019 non-G
Read more →-HSIC
Oct 21, 2019HENRY SCHEIN TO BE DISMISSED FROM SUMMIT COUNTY OPIOID LITIGATION Company to Make Donation to Establish Pain Management Education Foundation MELVILLE, N.Y.
HENRY SCHEIN TO BE DISMISSED FROM SUMMIT COUNTY OPIOID LITIGATION Company to Make Donation to Establish Pain Management Education Foundation MELVILLE, N.Y., October 21, 2019 Henry Schein, Inc. (Nasdaq: HSIC) announced today that the plaintiff has agreed to dismiss the Company
Read more →-HSIC
Aug 6, 2019AUGUST 6, 2019 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD SECOND QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS GAAP diluted EPS from continuing operations of $0.78, up 8.3 % over prior-ye
HENRY SCHEIN REPORTS RECORD SECOND QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS diluted EPS from continuing operations of $0.78, up 8.3% over prior-year GAAP diluted EPS from continuing operations diluted EPS from continuing operations of $0.84, up 10.5% over pri
Read more →-HSIC
May 7, 2019MAY 7, 2019 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FIRST QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Q1 GAAP net income per diluted share from continuing operations of $0.78 versus
HENRY SCHEIN REPORTS RECORD FIRST QUARTER 2019 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Q1 GAAP net income per diluted share from continuing operations of $0.78 versus prior-year GAAP net income per diluted share from continuing operations of $0.72 Q1 non-GAAP diluted EPS
Read more →-HSIC
Feb 20, 2019DATED FEBRUARY 20, 2019 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS Q4 GAAP net income per diluted share of $0.87 versus prior-year GAAP net loss pe
HENRY SCHEIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS Q4 GAAP net income per diluted share of $0.87 versus prior-year GAAP net loss per share of $0.06 Q4 non-GAAP diluted EPS of $1.12 versus prior-year non-GAAP diluted EPS of $0.97 Introduces 2019 no
Read more →-HSIC
Nov 6, 2018DATED NOVEMBER 6, 2018 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD THIRD QUARTER 2018 FINANCIAL RESULTS GAAP diluted EPS of $0.79 declined by 9.2% over prior-year GAAP diluted EPS Non-GAAP diluted EPS
HENRY SCHEIN REPORTS RECORD THIRD QUARTER 2018 FINANCIAL RESULTS GAAP diluted EPS of $0.79 declined by 9.2% over prior-year GAAP diluted EPS Non-GAAP diluted EPS of $1.03 increased by 18.4% over prior-year non-GAAP diluted EPS Company affirms 2018 non-GAAP diluted EPS guidance
Read more →-HSIC
Aug 30, 2018HENRY SCHEIN ANTICIPATES SETTLING PROPOSED CLASS-ACTION LITIGATION Company Expects to Record a Charge of $38.5 Million Pre-Tax or $0.19 Per Share in Third Quarter of 2018; Company Denies Any Wrongdoing MELVILLE, N.Y.
HENRY SCHEIN ANTICIPATES SETTLING PROPOSED CLASS-ACTION LITIGATION Company Expects to Record a Charge of $38.5 Million Pre-Tax or $0.19 Per Share in Third Quarter of 2018; Company Denies Any Wrongdoing MELVILLE, N.Y., August 30, 2018 Henry Schein, Inc. (Nasdaq:HSIC) announced
Read more →-HSIC
Aug 6, 2018DATED AUGUST 6, 2018 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD SECOND QUARTER 2018 FINANCIAL RESULTS GAAP diluted EPS of $0.92 increased by 7.0% over prior-year GAAP diluted EPS Non-GAAP diluted EPS
HENRY SCHEIN REPORTS RECORD SECOND QUARTER 2018 FINANCIAL RESULTS GAAP diluted EPS of $0.92 increased by 7.0% over prior-year GAAP diluted EPS Non-GAAP diluted EPS of $1.04 grew by 18.2% over prior-year non-GAAP diluted EPS Company raises bottom end of 2018 non-GAAP diluted EP
Read more →-HSIC
May 8, 2018DATED MAY 8, 2018 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FIRST QUARTER 2018 FINANCIAL RESULTS GAAP diluted EPS of $0.91 up 3.4% over prior-year GAAP diluted EPS, non-GAAP diluted EPS of $0.95 up
HENRY SCHEIN REPORTS RECORD FIRST QUARTER 2018 FINANCIAL RESULTS GAAP diluted EPS of $0.91 up 3.4% over prior-year GAAP diluted EPS, non-GAAP diluted EPS of $0.95 up 8.0% over prior-year non-GAAP diluted EPS Excluding costs related to restructuring and the spin-off and merger o
Read more →-HSIC
Apr 23, 2018Safe Harbor Statement Forward Looking Statements In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important fa
HENRY SCHEIN TO SPIN OFF AND MERGE ITS ANIMAL HEALTH BUSINESS WITH VETS FIRST CHOICE, CREATING AN INNOVATIVE APPROACH TO ADVANCING VETERINARY CARE April 23, 2018 EXHIBIT 99.1 Safe Harbor Statement Forward Looking Statements In accordance with the "Safe Harbor" provisions of th
Read more →-HSIC
Feb 20, 2018DATED FEBRUARY 20, 2018 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS Raises 2018 diluted EPS guidance range to reflect the impact of U.S. tax reform
HENRY SCHEIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS Raises 2018 diluted EPS guidance range to reflect the impact of U.S. tax reform legislation MELVILLE, N.Y., February 20, 2018 - Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of hea
Read more →-HSIC
Feb 13, 2018Can you comment on the FTC complaint that alleges Henry Schein, Benco and Patterson violated U.S. antitrust laws by conspiring to refuse to provide discounts to or otherwise serve dental buying groups representing dental
Can you comment on the FTC complaint that alleges Henry Schein, Benco and Patterson violated U.S. antitrust laws by conspiring to refuse to provide discounts to or otherwise serve dental buying groups representing dental practitioners? How many dental buying groups do you work
Read more →-HSIC
Nov 6, 2017DATED NOVEMBER 6, 2017 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD THIRD QUARTER FINANCIAL RESULTS Adjusts 2017 full year diluted EPS guidance range, introduces 2018 diluted EPS guidance MELVILLE, N.Y
HENRY SCHEIN REPORTS RECORD THIRD QUARTER FINANCIAL RESULTS Adjusts 2017 full year diluted EPS guidance range, introduces 2018 diluted EPS guidance MELVILLE, N.Y., November 6, 2017 - Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care products and ser
Read more →-HSIC
Aug 16, 2017HENRY SCHEIN ANNOUNCES 2-FOR-1 STOCK SPLIT Trading on a split-adjusted basis to begin
HENRY SCHEIN ANNOUNCES 2-FOR-1 STOCK SPLIT Trading on a split-adjusted basis to begin September 15, 2017 MELVILLE, N.Y., August 16, 2017 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care products and services to office-based dental, animal health a
Read more →-HSIC
Aug 8, 2017DATED AUGUST 8, 2017 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD SECOND QUARTER FINANCIAL RESULTS GAAP diluted EPS of $1.71 up 17.1% over prior-year GAAP diluted EPS; non-GAAP diluted EPS of $1.75 up
HENRY SCHEIN REPORTS RECORD SECOND QUARTER FINANCIAL RESULTS GAAP diluted EPS of $1.71 up 17.1% over prior-year GAAP diluted EPS; non-GAAP diluted EPS of $1.75 up 6.7% over prior-year non-GAAP diluted EPS MELVILLE, N.Y., August 8, 2017 - Henry Schein, Inc. (Nasdaq: HSIC), the w
Read more →-HSIC
May 9, 2017DATED MAY 9, 2017 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FIRST QUARTER FINANCIAL RESULTS First quarter 2017 GAAP diluted EPS of $1.76 up 28.5% over prior-year GAAP diluted EPS, up 24.8% over prio
HENRY SCHEIN REPORTS RECORD FIRST QUARTER FINANCIAL RESULTS First quarter 2017 GAAP diluted EPS of $1.76 up 28.5% over prior-year GAAP diluted EPS, up 24.8% over prior-year non-GAAP diluted EPS Affirms 2017 diluted EPS guidance range representing 16% to 18% growth over 2016 GAA
Read more →-HSIC
Apr 19, 2017HENRY SCHEIN ANNOUNCES NEW $750
HENRY SCHEIN ANNOUNCES NEW $750 MILLION CREDIT FACILITY MELVILLE, N.Y., April 19, 2017 Henry Schein, Inc. (Nasdaq: HSIC), the world s largest provider of health care products and services to office-based dental, animal health, and medical practitioners, today announced that it
Read more →-HSIC
Feb 21, 2017DATED FEBRUARY 21, 2017 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS Fourth quarter GAAP diluted EPS up 10.9% to $1.73, non-GAAP diluted EPS up 12.6%
HENRY SCHEIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS Fourth quarter GAAP diluted EPS up 10.9% to $1.73, non-GAAP diluted EPS up 12.6% to $1.88 Affirms 2017 diluted EPS guidance range representing growth of 16% to 18% compared to 2016 GAAP diluted EPS
Read more →-HSIC
Nov 2, 2016DATED NOVEMBER 2, 2016 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD THIRD QUARTER FINANCIAL RESULTS GAAP diluted EPS up 7.2% to $1.63, adjusted non-GAAP diluted EPS up 8.4% to $1.68 Affirms 2016 adjust
HENRY SCHEIN REPORTS RECORD THIRD QUARTER FINANCIAL RESULTS GAAP diluted EPS up 7.2% to $1.63, adjusted non-GAAP diluted EPS up 8.4% to $1.68 Affirms 2016 adjusted non-GAAP EPS guidance range Introduces 2017 EPS guidance representing year-over-year growth of 17% to 19% on a GA
Read more →-HSIC
Aug 4, 2016DATED AUGUST 4, 2016
HENRY SCHEIN REPORTS SECOND QUARTER FINANCIAL RESULTS MELVILLE, N.Y., August 4, 2016 - Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reported financial r
Read more →-HSIC
May 3, 2016DATED MAY 3, 2016 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD FIRST QUARTER RESULTS Adjusted EPS up 10.2% to $1.41 Affirms 2016 guidance range MELVILLE, N.Y.
HENRY SCHEIN REPORTS RECORD FIRST QUARTER RESULTS Adjusted EPS up 10.2% to $1.41 Affirms 2016 guidance range MELVILLE, N.Y., May 3, 2016 - Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal heal
Read more →Competitive Position
How HSIC ranks across every disease it competes inCompetitive Position is a premium feature
See how HSIC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial